Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum-resistant ovarian cancer (PROC)

被引：0
|
作者：
Hilbert, F. [1 ]
Gropp-Meier, M. [2 ]
Schmalfeldt, B. [2 ]
Rau, J. [3 ]
Meier, W. [4 ]
Hasenburg, A. [5 ]
Belau, A. [6 ]
Vergote, I. [7 ]
Zorr, A. [8 ]
Hils, R. [9 ]
Gerber, B. [10 ]
du Bois, A. [11 ]
Marme, F. [12 ]
Mahner, S. [13 ]
Canzler, U. [14 ]
Lueck, H. -J. [15 ]
Grischke, E. -M [16 ]
Kurzeder, C. [11 ]
机构：
[1] UKSH Campus Kiel, Klin Gynakol & Geburtshilfe, Kiel, Germany
[2] Gynakol Onkol & Brustzentrum, Oberschwabenklin, Ravensburg, Germany
[3] Univ Marburg, KKS, Marburg, Germany
[4] Evangel Krankenhaus, Frauenklin, Dusseldorf, Germany
[5] Univ Klin, Frauenklin, Freiburg, Germany
[6] Ernst Moritz Arndt Univ Greifswald, Univ Klinikum Greifswald, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Greifswald, Germany
[7] Univ Hosp, Gynecol Oncol, Leuven, Belgium
[8] Klinikum Konstanz, Frauenklin, Constance, Germany
[9] HSK, Gynakol & Gynakol Onkol, Wiesbaden, Germany
[10] Klinikum Sudstadt, Univ Frauenklin & Poliklin, Rostock, Germany
[11] Kliniken Essen Mitte, Klin Gynakol Onkol, Essen, Germany
[12] Univ Frauenklin, Natl Ctr Tumorerkrankungen, Heidelberg, Germany
[13] Klinikum Univ Munchen, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany
[14] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Dresden, Germany
[15] Gynakol Onkol Praxis Pelikanpl, Hannover, Germany
[16] Univ Klinikum Tubingen, Univ Frauenklin, Tubingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0087
引用
收藏
页码：138 / 138
页数：1
相关论文
共 46 条
  • [1] PATIENT-REPORTED OUTCOME (PRO) RESULTS FROM THE AGO-OVAR 2.20/ENGOT-OV14/PENELOPE DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY ± PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC)
    Hilpert, F.
    Greimel, E.
    Ottevanger, P.
    Rau, J.
    Lorusso, D.
    Kroep, J.
    Mirza, M. Raza
    Zeimet, A.
    Mitchell, L.
    Kurzeder, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 465 - 466
  • [2] SUBGROUP ANALYSIS BY CHEMOTHERAPY COHORT IN THE AGO-OVAR 2.20/ENGOT-OV14/PENELOPE DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY ± PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC)
    Pautier, P.
    Pardo, B.
    Hilpert, F.
    Rau, J.
    Gadducci, A.
    Savarese, A.
    Ottevanger, P.
    Kristensen, G.
    Berger, R.
    Bastiere-Truchot, L.
    Mitchell, L.
    Kurzeder, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 24 - 26
  • [3] Chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase 3 trial
    Mahner, S.
    Lueck, H. -J.
    Grischke, E. -M.
    Rau, J.
    Gropp-Meier, M.
    Schmalfeldt, B.
    Meier, W.
    Hasenburg, A.
    Belau, A.
    Vergote, I.
    Zorr, A.
    Huels, R.
    Gerber, B.
    du Bois, A.
    Marme, F.
    Hilpert, F.
    Canzler, U.
    Kurzeder, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 97 - 97
  • [4] Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ ENGOT-ov14/ PENELOPE double-blind placebo-controlled randomized phase III trial.
    Kurzeder, Christian
    Bover, Isabel
    Marme, Frederik
    Rau, Joern
    Pautier, Patricia
    Colombo, Nicoletta
    Lorusso, Domenica
    Ottevanger, Petronella
    Bjurberg, Maria
    Marth, Christian
    Barretina-Ginesta, Pilar
    Vergote, Ignace
    Floquet, Anne
    Del Campo, Jose Maria
    Mahner, Sven
    Bastiere-Truchot, Lydie
    Mitchell, Lada
    Polleis, Sandra
    Du Bois, Andreas
    Gonzalez-Martin, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.
    Kuzeder, Christian
    Del Campo, Jose Maria
    Pautier, Patricia
    Hilpert, Felix
    Gadducci, Angiolo
    Ottevanger, Petronella
    Lorusso, Damonice
    Vergote, Ignace
    Bover, Isabel
    Fabbro, Miami
    Marme, Frederik
    Garcia, Yolanda
    Salle, Frederic
    Gropp-Meier, Martina
    Pardo, Beatriz
    Freudensprung, Ulrich
    Walker, Ru-Amir
    Gonzalez-Martin, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] FINAL OVERALL SURVIVAL RESULTS FROM the DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III PENELOPE TRIAL EVALUATING PERTUZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER WITH LOW TUMOUR HER3 mRNA EXPRESSION
    Lorusso, D.
    Gonzalez-Martin, A.
    Lueck, H. J.
    Rau, J.
    Selle, F.
    Colombo, N.
    Ottevanger, P.
    Mirza, M. R.
    Berger, R.
    Garcia-Donas, J.
    Grischke, E. M.
    Berton-Rigaud, D.
    Redondo, A.
    Vergote, I.
    Poveda, A.
    Bastiere-Truchot, L.
    Cardona, A.
    du Bois, A.
    Kurzeder, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 11 - 12
  • [7] Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
    Ray-Coquard, Isabelle
    Cibula, David
    Mirza, Mansoor R.
    Reuss, Alexander
    Ricci, Caterina
    Colombo, Nicoletta
    Koch, Horst
    Goffin, Frederic
    Gonzalez-Martin, Antonio
    Ottevanger, Petronella B.
    Baumann, Klaus
    Bjorge, Line
    Lesoin, Anne
    Burges, Alexander
    Rosenberg, Per
    Gropp-Meier, Martina
    Harrela, Maija
    Harter, Philipp
    Frenel, Jean-Sebastien
    Minarik, Tomas
    Pisano, Carmela
    Hasenburg, Annette
    Merger, Michael
    du Bois, Andreas
    Kristensen, Gunnar
    Bidzinski, Mariusz
    Helpianska, Lydia
    Kutarska, Elzbieta
    Flynn, Patrick
    Hils, Rita
    Malander, Susanne
    Scambia, Giovanni
    Tredan, Olivier
    Bamias, Aristotelis
    Wimberger, Pauline
    Joly, Florence
    Abu-Khalaf, Maysa
    Lisyanskaya, Alla
    Vergote, Ignace
    Pippitt, Charles H.
    Fiane, Bent
    Teneriello, Michael
    Janni, Wolfgang
    Rushing, Scott
    Herwig, Uwe
    Ghamande, Sharad
    Nicoletto, Maria Ornella
    Pfisterer, Jacobus
    Peters, Martin
    Tewari, Krishnansu
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (02) : 439 - 448
  • [8] BIOMARKER RESULTS FROM PENELOPE, A RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY plus /- PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC) WITH LOW TUMOUR HER3 MRNA EXPRESSION
    Colombo, N.
    Gonzalez-Martin, A.
    Oestergaard, M. Z.
    Rau, J.
    Canzler, U.
    Fabbro, M.
    Martinez, J.
    Kiermaier, A.
    Mitchell, L.
    Kurzeder, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 415 - 417
  • [9] Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
    du Bois, Andreas
    Kristensen, Gunnar
    Ray-Coquard, Isabelle
    Reuss, Alexander
    Pignata, Sandro
    Colombo, Nicoletta
    Denison, Ursula
    Vergote, Ignace
    del Campo, Jose M.
    Ottevanger, Petronella
    Heubner, Martin
    Minarik, Thomas
    Sevin, Emmanuel
    de Gregorio, Nikolaus
    Bidzinski, Mariusz
    Pfisterer, Jacobus
    Malander, Susanne
    Hilpert, Felix
    Mirza, Mansoor R.
    Scambia, Giovanni
    Meier, Werner
    Nicoletto, Maria O.
    Bjorge, Line
    Lortholary, Alain
    Sailer, Martin Oliver
    Merger, Michael
    Harter, Philipp
    LANCET ONCOLOGY, 2016, 17 (01): : 78 - 89
  • [10] Biomarker results from PENELOPE, A randomised phase III trial evaluating chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC) with low tumor HER3 mRNA expression
    Marme, F.
    Grischke, E-M
    Gropp-Meier, M.
    Rau, J.
    Schmalfeldt, B.
    Meier, W.
    Hasenburg, A.
    Belau, A.
    Vergote, I.
    Zorr, A.
    Hils, R.
    Gerber, B.
    du Bois, A.
    Mahner, S.
    Hilpert, F.
    Canzler, U.
    Lueck, H. -J
    Kurzeder, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 94 - 94
12345